Christine Hansen advises leading pharmaceutical and chemical companies on global intellectual property matters. She strategizes with her clients to focus patent protection on business goals. She is trusted with patent due diligence investigations for multi-million-dollar investments in new biotech and chemical technology. In 2011, she was named a Top Patent Prosecutor by Patent Research Review.
Christine assimilates complex business and legal matters to provide clear, practical advice to her clients. She drafts license agreements that address possible scenarios in a complex international business world, but are not complicated to understand and follow.
She is often called on for thorough freedom-to-operate investigations before the U.S. launch of sophisticated pharmaceutical products. She uses her background in biology and chemistry from undergraduate studies at Princeton University and post-graduate studies at the University of Marburg, Germany to provide strong legal solutions involving tough technical questions.
Christine’s broad experience sets her apart as a choice for patent counseling.
- Early in her career, she litigated a tort case for a U.S. client involving a representation to a German packaging customer. She identified a new legal theory for her client based on choice of law that greatly reduced her client’s damage exposure. The case settled favorably. She deposed witnesses in litigation involving recycled plastic processing and cross-examined the technical expert at the jury trial in the District Court for the District of Delaware. She supervised 6-10 temporary attorneys in extensive discovery production in patent litigation against IBM involving very early computer architecture patents.
- In representing an alleged patent infringer in the District Court for the Eastern District of Michigan, on her own initiative Christine investigated the judge’s summary judgment record and identified a consistent trend of splitting issues on summary judgment. As a result, Christine and her team moved for summary judgment of patent invalidity on two grounds, and, as expected, succeeded on one ground to invalidate the patent.
Following her strong scientific interests, Christine joined the patent prosecution section of a prominent patent boutique. The patent boutique had many German clients who benefited from her experience working as a chemical assistant at Hoechst in Germany and studying in Germany. Subsequently, she was recruited to join Rhone-Poulenc-Rorer as in-house patent opinion counsel. While at RPR, Christine supported the introduction of new syringes to deliver the company’s largest selling product by providing extensive due diligence and patent freedom-to-operate opinions on safety syringes. She appreciates teamwork and has an insight into the corporate environment as a result of her work at RPR and of being a member there of a tight-knit patent team with a strong leader.
- Christine has advised clients on freedom-to-operate for polymerase chain reaction (PCR) tests for plasma samples, plasma-protein products, medical devices and genetically modified crops, among other technology.
- She has assumed responsibilities of senior in-house patent counsel during leaves and absences until a replacement can be hired.
- Christine argued before the U.S. Board of Patent Appeals and Interferences and overcame obviousness rejections to obtain a plasma-product patent that was the basis of a client’s exclusivity for its largest selling product.
- While managing a patent portfolio for a plasma-products company, Christine teamed with European counsel to overcome an Opposition challenge to uphold the client’s crucial process patent.
- Christine provided complex freedom-to-operate risk evaluations for products targeting obesity, cardiovascular illness and women’s health (hormone patches).
Christine uses her experience to advise start-up clients on patent strategies and licensing. She is a trusted advisor to a start-up company that will produce personalized pharmaceutical capsules to simplify administration of multiple drugs at multiple times. She reaches out to connect with the company’s business partners whenever possible, such as adding a day to a European business trip to visit the client’s potential Belgian investor. Through her pharmaceutical connections and the firm’s deep life sciences practice, Christine connects start-up companies with resources they need.
She is the head of the firm's Wilmington office.
In 2015, Christine was recommended by IAM’s Patent 1000 list – the best-in-class listing of patent prosecution, licensing and litigation practitioners. In 2017, she was the recipient of the Lexology Client Choice Award of Intellectual Property - Patents in Delaware. The award recognizes law firms and partners for excellence in client service.
Christine is committed to the community. In addition to being a past board member of the Girl Scouts of the Chesapeake Bay Council, she volunteers with the Michael J. Fox Foundation for Parkinson’s Research.
Christine speaks German, conversationally, and is a fluent reader of technical German.
Other Representative Matters
- FDA Orange Book submissions for New Drugs.
- Patent Term Extension Applications for blockbuster drugs.
- Responsible for U.S. patent prosecution for all patents relating to blockbuster anticoagulant (annual U.S. sales of about $850 million).
- Coordinate and Analyze Patent Freedom-to-operate for client’s protein drug (annual U.S. sales of about $400 million).
University of Pennsylvania Law School, J.D., 1992, cum laude
Princeton University, A.B., Chemistry
Philipps Universitaet, Marburg Germany (Fulbright Scholar)
- United States Patent and Trademark Office
- U.S. District Court for the District of Delaware
- U.S. Court of Appeals for the Federal Circuit
American Bar Association
Intellectual Property Owners Association
Delaware State Bar Association
Philadelphia Intellectual Property Law Association